{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:57Z","timestamp":1790456097090,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":142,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"USV private limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02086-3","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T06:22:38Z","timestamp":1768112558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of fixed-dose dapagliflozin\u2013pioglitazone in Indian adults with type 2 diabetes: a phase 3 PRO-1 trial"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-4536","authenticated-orcid":false,"given":"Awadhesh Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-7110","authenticated-orcid":false,"given":"Krishna G","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-9639","authenticated-orcid":false,"given":"A G","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-6391","authenticated-orcid":false,"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-121X","authenticated-orcid":false,"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-5821","authenticated-orcid":false,"given":"Shashank R","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3772-2659","authenticated-orcid":false,"given":"Kaushik","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5471-0695","authenticated-orcid":false,"given":"Rakesh K","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7785-8311","authenticated-orcid":false,"given":"Vijay K","family":"Panikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-3212","authenticated-orcid":false,"given":"Ambrish","family":"Mithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4903-7144","authenticated-orcid":false,"given":"Smriti","family":"Gadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0756-2089","authenticated-orcid":false,"given":"Thamburaj","family":"Anthuvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"issue":"3","key":"2086_CR1","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.clinre.2025.102304","volume":"49","author":"MS Abdel Monem","year":"2025","unstructured":"Abdel Monem MS, Adel A, Abbassi MM, Abdelaziz DH, Hassany M, Raziky ME, et al. Efficacy and safety of Dapagliflozin compared to Pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial. Clin Res Hepatol Gastroenterol. 2025;49(3):102543. https:\/\/doi.org\/10.1016\/j.clinre.2025.102304.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"2086_CR2","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.18203\/2394-6040.ijcmph20241211","volume":"11","author":"SR Kiran","year":"2024","unstructured":"Kiran SR, Sureka RK. Prevalence of diabetes mellitus and its associated comorbidities: a population based study. Int J Community Med Public Health. 2024;11(5):2085\u201390. https:\/\/doi.org\/10.18203\/2394-6040.ijcmph20241211.","journal-title":"Int J Community Med Public Health"},{"issue":"12","key":"2086_CR3","doi-asserted-by":"publisher","first-page":"e1352","DOI":"10.1016\/S2214-109X(18)30387-5","volume":"6","author":"India State-Level Disease Burden Initiative Diabetes Collaborators","year":"2018","unstructured":"India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the States of india: the global burden of disease study 1990\u20132016. Lancet Glob Health. 2018;6(12):e1352\u201362. https:\/\/doi.org\/10.1016\/S2214-109X(18)30387-5.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"2086_CR4","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.4103\/jfmpc.jfmpc_2010_20","volume":"10","author":"B Saboo","year":"2021","unstructured":"Saboo B, Agarwal S, Gupta S, Makkar B, Panneerselvam A, Sahoo AK, et al. REAL-world evidence of risk factors and comorbidities in YOUNG Indian adults with type 2 diabetes mellitus: A REAL YOUNG (diabetes) study. J Family Med Prim Care. 2021;10(9):3444\u201352. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2010_20.","journal-title":"J Family Med Prim Care"},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"847692","DOI":"10.3389\/fendo.2022.847692","volume":"13","author":"V Venkatesan","year":"2022","unstructured":"Venkatesan V, Lopez-Alvarenga JC, Arya R, Ramu D, Koshy T, Ravichandran U, et al. Burden of type 2 diabetes and associated cardiometabolic traits and their heritability estimates in endogamous ethnic groups of india: findings from the INDIGENIUS consortium. Front Endocrinol (Lausanne). 2022;13:847692. https:\/\/doi.org\/10.3389\/fendo.2022.847692.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2086_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","volume":"11","author":"RM Anjana","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of india: the ICMR-INDIAB National cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u201389. https:\/\/doi.org\/10.1016\/S2213-8587(23)00119-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2086_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4103\/2230-8210.129715","volume":"18","author":"V Mohan","year":"2014","unstructured":"Mohan V, Shah SN, Joshi SR, Seshiah V, Sahay BK, Banerjee S, et al. Current status of management, control, complications and psychosocial aspects of patients with diabetes in india: results from the DiabCare India 2011 study. Indian J Endocrinol Metab. 2014;18(3):370\u20138. https:\/\/doi.org\/10.4103\/2230-8210.129715.","journal-title":"Indian J Endocrinol Metab"},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"120956","DOI":"10.1016\/j.lfs.2022.120956","volume":"308","author":"HH Shaaban","year":"2022","unstructured":"Shaaban HH, Alzaim I, El-Mallah A, Aly RG, El-Yazbi AF, Wahid A. Metformin, pioglitazone, Dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. Life Sci. 2022;308:120956. https:\/\/doi.org\/10.1016\/j.lfs.2022.120956.","journal-title":"Life Sci"},{"issue":"1","key":"2086_CR9","doi-asserted-by":"publisher","first-page":"100167","DOI":"10.1016\/j.ejmcr.2024.100167","volume":"11","author":"N Maksud","year":"2024","unstructured":"Maksud N, Bera S, Naim M, Alam O, Dapagliflozin. A new hope for the therapeutic treatment of type 2 diabetes mellitus. Eur J Med Chem Rep. 2024;11(1):100167. https:\/\/doi.org\/10.1016\/j.ejmcr.2024.100167.","journal-title":"Eur J Med Chem Rep"},{"issue":"5","key":"2086_CR10","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.12652","volume":"18","author":"RA DeFronzo","year":"2016","unstructured":"DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder REJ, Abdul-Ghani M. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab. 2016;18(5):454\u201362. https:\/\/doi.org\/10.1111\/dom.12652.","journal-title":"Diabetes Obes Metab"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"1111430","DOI":"10.3389\/fendo.2023.1111430","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Du H, Zhao Y, Ren Y, Ma C, Chen H, et al. Response to Pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1111430. https:\/\/doi.org\/10.3389\/fendo.2023.1111430.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.5114\/amsad\/202298","volume":"10","author":"GS Papaetis","year":"2025","unstructured":"Papaetis GS, Picolos MK, Sacharidou A. Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes? Arch Med Sci Atheroscler Dis. 2025;10:e1\u201315. https:\/\/doi.org\/10.5114\/amsad\/202298.","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"9","key":"2086_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.clinthera.2024.06.023","volume":"46","author":"YK Cho","year":"2024","unstructured":"Cho YK, Kim KS, Lee BW, Hong JH, Yu JM, Lim S, et al. Efficacy and safety of Pioglitazone Add-on in patients with type 2 diabetes mellitus inadequately controlled with Metformin and dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled study. Clin Ther. 2024;46(9):662\u20139. https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.023.","journal-title":"Clin Ther"},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"110685","DOI":"10.1016\/j.diabres.2023.110685","volume":"200","author":"SC Lo","year":"2023","unstructured":"Lo SC, Kornelius E, Liao PL, Huang JY, Yang YS, Huang CN, Pioglitazone. SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. 2023;200:110685. https:\/\/doi.org\/10.1016\/j.diabres.2023.110685.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2086_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/30502071241281419","volume":"1","author":"KG Seshadri","year":"2024","unstructured":"Seshadri KG, Padhye D, Tippisetty S, Polisetti S, Gadia S. Effects of SGLT2i and Pioglitazone on FIB-4 index in patients with metabolic dysfunction associated steatotic liver Disease\u2014A real world retrospective study from India. Int J Clin Metabolism Diabetes. 2024;1(1):11\u20139. https:\/\/doi.org\/10.1177\/30502071241281419.","journal-title":"Int J Clin Metabolism Diabetes"},{"issue":"5","key":"2086_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.12875","volume":"19","author":"L Ji","year":"2017","unstructured":"Ji L, Li L, Kuang J, Yang T, Kim DJ, Kadir AA, et al. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. Diabetes Obes Metab. 2017;19(5):754\u20138. https:\/\/doi.org\/10.1111\/dom.12875.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2086_CR17","doi-asserted-by":"publisher","first-page":"e0250993","DOI":"10.1371\/journal.pone.0250993","volume":"16","author":"AK B\u00f6hm","year":"2021","unstructured":"B\u00f6hm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLoS ONE. 2021;16(5):e0250993. https:\/\/doi.org\/10.1371\/journal.pone.0250993.","journal-title":"PLoS ONE"},{"key":"2086_CR18","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guidelines on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]. European Medicines Agency; 2024 [cited Sep 23, 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf"},{"issue":"7","key":"2086_CR19","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2337\/dc11-1693","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on Pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473\u20138. https:\/\/doi.org\/10.2337\/dc11-1693.","journal-title":"Diabetes Care"},{"issue":"5","key":"2086_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4093\/dmj.2023.0314","volume":"48","author":"JH Heo","year":"2024","unstructured":"Heo JH, Han KA, Hong JH, Seo HA, Hong EG, Yu JM, et al. Pioglitazone as Add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with Dapagliflozin and metformin: Double-Blind, Randomized, Placebo-Controlled trial. Diabetes Metab J. 2024;48(5):937\u201348. https:\/\/doi.org\/10.4093\/dmj.2023.0314.","journal-title":"Diabetes Metab J"},{"issue":"4","key":"2086_CR21","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1111\/dom.16218","volume":"27","author":"R Sahay","year":"2025","unstructured":"Sahay R, Gangwani D, Singh M, Gupta S, Kale N, Srivastava M, et al. Fixed dose combination of dapagliflozin, glimepiride and extended-release Metformin tablets in patients with type 2 diabetes poorly controlled by Metformin and glimepiride: A phase III, open label, randomized clinical study in India. Diabetes Obes Metab. 2025;27(4):2193\u2013205. https:\/\/doi.org\/10.1111\/dom.16218.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2086_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/00325481.2020.1785650","volume":"132","author":"I Lingvay","year":"2020","unstructured":"Lingvay I, Beetz N, Sennewald R, Schuler-Metz A, Bertulis J, Loley C, et al. Triple fixed-dose combination empagliflozin, linagliptin, and Metformin for patients with type 2 diabetes. Postgrad Med. 2020;132(4):337\u201345. https:\/\/doi.org\/10.1080\/00325481.2020.1785650.","journal-title":"Postgrad Med"},{"issue":"7","key":"2086_CR23","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1111\/dom.15576","volume":"26","author":"M Anson","year":"2024","unstructured":"Anson M, Henney AE, Zhao SS, Ibarburu GH, Lip GYH, Cuthbertson DJ, et al. Effect of combination Pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. Diabetes Obes Metab. 2024;26(7):2606\u201323. https:\/\/doi.org\/10.1111\/dom.15576.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2086_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dom.12254","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Efficacy and safety of Canagliflozin over 52 weeks in patients with type 2 diabetes on background Metformin and Pioglitazone. Diabetes Obes Metab. 2014;16(5):467\u201377. https:\/\/doi.org\/10.1111\/dom.12254.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2086_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s13340-014-0182-y","volume":"6","author":"A Kashiwagi","year":"2015","unstructured":"Kashiwagi A, Shiga T, Akiyama N, Kazuta K, Utsuno A, Yoshida S, et al. Efficacy and safety of Ipragliflozin as an add-on to Pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int. 2015;6(2):104\u201316. https:\/\/doi.org\/10.1007\/s13340-014-0182-y.","journal-title":"Diabetol Int"},{"issue":"2","key":"2086_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/dom.12188","volume":"16","author":"CS Kovacs","year":"2014","unstructured":"Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to Pioglitazone or Pioglitazone plus Metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147\u201358. https:\/\/doi.org\/10.1111\/dom.12188.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2086_CR27","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1111\/dom.15526","volume":"26","author":"S Lim","year":"2024","unstructured":"Lim S, Lee SH, Min KW, Lee CB, Kim SY, Yoo HJ, et al. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of Pioglitazone add-on therapy in type 2 diabetic patients treated with Metformin and Dapagliflozin. Diabetes Obes Metab. 2024;26(6):2188\u201398. https:\/\/doi.org\/10.1111\/dom.15526.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2086_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dom.16049","volume":"27","author":"CH Lee","year":"2024","unstructured":"Lee CH, Lui D, Mak LYL, Fong C, Chan K, Mak J, et al. Benefits of combining SGLT2 inhibitors and Pioglitazone on risk of MASH in type 2 diabetes\u2014A real-world study. Diabetes Obes Metabolism. 2024;27(2):574\u201382. https:\/\/doi.org\/10.1111\/dom.16049.","journal-title":"Diabetes Obes Metabolism"},{"issue":"5","key":"2086_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1517\/14740338.2015.1020294","volume":"14","author":"T Blevins","year":"2015","unstructured":"Blevins T. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to Pioglitazone or Pioglitazone plus Metformin. Expert Opin Drug Saf. 2015;14(5):789\u201393. https:\/\/doi.org\/10.1517\/14740338.2015.1020294.","journal-title":"Expert Opin Drug Saf"},{"issue":"36","key":"2086_CR30","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of Dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41(36):3421\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa419.","journal-title":"Eur Heart J"},{"issue":"3","key":"2086_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/dom.13546","volume":"21","author":"M Abdul-Ghani","year":"2019","unstructured":"Abdul-Ghani M, Migahid O, Megahed A, Singh R, Fawaz M, DeFronzo RA, et al. Pioglitazone prevents the increase in plasma ketone concentration associated with Dapagliflozin in insulin-treated T2DM patients: results from the Qatar study. Diabetes Obes Metab. 2019;21(3):705\u20139. https:\/\/doi.org\/10.1111\/dom.13546.","journal-title":"Diabetes Obes Metab"},{"key":"2086_CR32","doi-asserted-by":"publisher","unstructured":"Vaidya V, Anupindi VR, Pinto S, Kaun M. Cost utility analysis of fixed-dose and free-dose combinations of oral medications in type 2 diabetes patients. J Pharm Health Serv Res. 2016;7(3). https:\/\/doi.org\/10.1111\/jphs.12139.","DOI":"10.1111\/jphs.12139"},{"issue":"3","key":"2086_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3111\/13696998.2015.1109518","volume":"19","author":"T Lokhandwala","year":"2016","unstructured":"Lokhandwala T, Smith N, Sternhufvud C, S\u00f6rstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203\u201312. https:\/\/doi.org\/10.3111\/13696998.2015.1109518.","journal-title":"J Med Econ"},{"issue":"7","key":"2086_CR34","first-page":"40","volume":"21","author":"SA Williams","year":"2012","unstructured":"Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40\u20138.","journal-title":"Manag Care"},{"issue":"6","key":"2086_CR35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","volume":"27","author":"V Hutchins","year":"2011","unstructured":"Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157\u201368. https:\/\/doi.org\/10.1185\/03007995.2011.570745.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2086_CR36","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1185\/03007995.2011.628306","volume":"27","author":"W Zhang","year":"2011","unstructured":"Zhang W, Xing SS, Wang HJ, Xing QC. Fixed-dose single tablet combinations: an alternative for initial therapy of patients with type 2 diabetes? Curr Med Res Opin. 2011;27(12):2321\u20132. https:\/\/doi.org\/10.1185\/03007995.2011.628306.","journal-title":"Curr Med Res Opin"},{"key":"2086_CR37","doi-asserted-by":"publisher","first-page":"1156081","DOI":"10.3389\/fphar.2023.1156081","volume":"14","author":"Q Wei","year":"2023","unstructured":"Wei Q, Zhou J, Li H, Wang L, Wu Y, Ma A, et al. Medication adherence with fixed-dose versus free-equivalent combination therapies: systematic review and meta-analysis. Front Pharmacol. 2023;14:1156081. https:\/\/doi.org\/10.3389\/fphar.2023.1156081.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2086_CR38","first-page":"16","volume":"24","author":"DS Kalra","year":"2024","unstructured":"Kalra DS, Baruah DMP, Sahay DR, Marwah DT, Swami DP, Patil DS, et al. Consensus on ongoing educational practices to improve SGLT2i adherence in india: consensus ONE SGLT2i adherence group. Asian J Diabetol. 2024;24(3):16\u201325.","journal-title":"Asian J Diabetol"},{"issue":"11","key":"2086_CR39","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4103\/jfmpc.jfmpc_843_20","volume":"9","author":"S Kalra","year":"2020","unstructured":"Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450\u20137. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_843_20.","journal-title":"J Family Med Prim Care"},{"issue":"4","key":"2086_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.59556\/japi.73.0887","volume":"73","author":"N Singh","year":"2025","unstructured":"Singh N, Singh A, Patni B, Agarwal P, Nageshappa M, Prasad M, et al. Consensus to reduce withdrawal and improve adherence with SGLT2i: consensus TWO SGLT2i adherence group. J Assoc Phys India. 2025;73(4):75\u201384. https:\/\/doi.org\/10.59556\/japi.73.0887.","journal-title":"J Assoc Phys India"},{"issue":"1","key":"2086_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40258-022-00760-x","volume":"21","author":"AK B\u00f6hm","year":"2023","unstructured":"B\u00f6hm AK, Schneider U, Stargardt T. Economic effects of Fixed-Dose versus Loose-Dose combination therapy for type 2 diabetes patients. Appl Health Econ Health Policy. 2023;21(1):109\u201318. https:\/\/doi.org\/10.1007\/s40258-022-00760-x.","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"2086_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.18553\/jmcp.2022.28.9.958","volume":"28","author":"S Edelman","year":"2022","unstructured":"Edelman S, Cassarino D, Kayne D, Dex T, Li X, Pasquel FJ. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28(9):958\u201368. https:\/\/doi.org\/10.18553\/jmcp.2022.28.9.958.","journal-title":"J Manag Care Spec Pharm"},{"key":"2086_CR43","doi-asserted-by":"publisher","first-page":"1420485","DOI":"10.3389\/fendo.2024.1420485","volume":"15","author":"YR Li","year":"2024","unstructured":"Li YR, Wang CC, Liu CH, Yen CL, Wu VCC, Huang EJC, et al. Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and Pioglitazone. Front Endocrinol (Lausanne). 2024;15:1420485. https:\/\/doi.org\/10.3389\/fendo.2024.1420485.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2086_CR44","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2147\/DDDT.S512872","volume":"19","author":"Y Lin","year":"2025","unstructured":"Lin Y, Shi J, Yu X, Sun J, Lixia S, Dou J, et al. Enhancing diabetes treatment: comparing Pioglitazone\/Metformin with Dapagliflozin versus basal Insulin\/Metformin in type 2 diabetes. Drug Des Devel Ther. 2025;19:1795\u2013808. https:\/\/doi.org\/10.2147\/DDDT.S512872.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"2086_CR45","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/jcm14061960","volume":"14","author":"LG Confederat","year":"2025","unstructured":"Confederat LG, Dragostin OM, Condurache MI. SGLT2 inhibitors and the risk of urogenital infections: A concise review. J Clin Med. 2025;14(6):1960. https:\/\/doi.org\/10.3390\/jcm14061960.","journal-title":"J Clin Med"},{"issue":"1","key":"2086_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, et al. Lack of Pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47\u201354. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01314.x.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02086-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02086-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02086-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:03:25Z","timestamp":1780434205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02086-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02086-3","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent form, and participant-facing materials were approved by the Institutional Ethics Committees of all the participating centers. Written informed consent was obtained from all participants prior to enrollment. The trial was prospectively registered in the Clinical Trials Registry, India (CTRI\/2024\/09\/073221).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Artificial intelligence tools were used only for language refinement and grammar editing during the preparation of the manuscript. No AI tools were used to develop scientific content, perform statistical analyses, generate results, or influence the study\u2019s design or interpretation. All analyses, conclusions, and interpretations were performed independently by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI use disclosure"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}